Tuesday, November 30, 2021
Slider
Home World Bharat Biotech To Soon Start Phase 3 Trials Of Its Covid-19 Vaccine

Bharat Biotech To Soon Start Phase 3 Trials Of Its Covid-19 Vaccine

Bharat Biotech has recently requested to Drugs Controller General of India for conducting phase 3 clinical trials of its COVID-19 vaccine.

The Company has been asked to first submit complete safety and immunogenicity data of the ongoing phase 2 trial, besides providing some clarifications, before proceeding for the next stage.

Covaxin is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.

The firm in its application said that the study would cover 28,500 subjects aged 18 years and above and would be conducted in 19 sites including Delhi, Mumbai, Patna and Lucknow across 10 states.

An official said: “The company presented phase 3 clinical trial protocol along with interim data of phase 1 and 2 clinical trials.”

The subject expert committee (SEC) at the Central Drugs Standard Control Organisation (CDSCO) deliberated on the application on October 5.

After a detailed deliberation, the committee opined that the design of the phase-3 study is in principle satisfactory except for clarification on definition of asymptomatic, etc.

“However, the study should be initiated with appropriate dose identified from the phase-2 safety and immunogenicity data. Accordingly, the firm should submit safety and immunogenicity data from phase-2 trial for consideration,” the panel said in its recommendations.

The SEC during its discussion also observed that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported so far, a source told news agency Press Trust of India.

The most common adverse event was pain at the injection site, which resolved transiently, the source told news agency PTI.

The phase-3 clinical trial application proposed a dose of 0.5 ml on day 0 and 28, sources told Press Trust of India.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Ranveer brings India’s greatest cricket story alive in ’83’ trailer

The trailer for Ranveer Singh-starrer film '83' is finally revealed bringing alive one of the most memorable moments of Indian cricket.Ranveer plays the role...

After declaring amnesty, Taliban hunt down Afghan security forces

The Taliban immediately executed some former security force members in front of their families or have left their bodies where they were likely to...

Pakistani model apologizes after her barehead photoshoot at Kartarpur Sahib Gurdwara triggers row

A Pakistani model has triggered controversary with her “barehead” photoshoot at Gurdwara Darbar Sahib in Kartarpur that has hurt the sentiments of the Sikh...

WHO: Delta variant still responsible for 99% of Covid-19 cases globally

While the world is on high alert due to the new Omicron Covid-19 strain, Delta variant continues to be a major cause of the...

Recent Comments